



## ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

March 31, 2025 at 4:30 PM EDT

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in April:

- **Needham's 24th Annual Healthcare Conference** – Presenting a company overview on Monday, April 7, 2025, at 1:30 p.m. ET
- **Stifel 2025 Virtual Targeted Oncology Forum** – Participating in a fireside chat on Wednesday, April 9, 2025, at 2:00 p.m. ET

Webcasts of the presentation and discussion will be available through the investor section of the company's website at [www.oricpharma.com](http://www.oricpharma.com). Replays of the webcasts will be available for 90 days following the event.

### About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by *Overcoming Resistance In Cancer*. ORIC's clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to [www.oricpharma.com](http://www.oricpharma.com), and follow us on [X](#) or [LinkedIn](#).

### Contact:

Dominic Piscitelli, Chief Financial Officer  
[dominic.piscitelli@oricpharma.com](mailto:dominic.piscitelli@oricpharma.com)  
[info@oricpharma.com](mailto:info@oricpharma.com)